← European Medicine Shortage Tracker · all medicines

Pazopanibhydrochlorid shortage — availability across Europe

Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.

MEDICALLY REVIEWED
Dr. Chrysoula I. Liakou MD, PhD
Internal Medicine Specialist
Cancer Immunology Researcher
Reviewed 30 July 2026 · next review due 30 January 2027

Pazopanibhydrochlorid currently has availability issues reported in 3 European registers: Germany, Spain, Italy.

Shortage  ATC L01EX03 · also listed as: Pazopanibhydrochlorid · PAZOPANIB · data refreshed 9 September 2026

Key facts

As of 9 September 2026, 3 of the 9 tracked registers list current availability issues for Pazopanibhydrochlorid, covering 5 affected product presentations. The longest-running open report was filed in Germany on 2026-04-01 and has now been open for about 5 months. Where agencies state a cause, manufacturing problems lead with 1 of the 1 stated-cause reports. The furthest expected-resolution date currently on file is 2026-09-29; the earliest is 2026-09-15. Momentum is current, not historical: 2 of the open reports were filed within the last 90 days. The issue spread across registers over time rather than at once: Germany reported first (2026-04-01), with Italy following roughly 4 months later — a pattern typical of supply problems cascading between national markets. Registers in Germany, Spain, Italy indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Pazopanibhydrochlorid is coded L01EX03 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.

WhereStatus & productsSinceExpected end Reason / alternativesSource
🇩🇪 GermanyShortage
Pazopanib Viatris 200 mg Filmtabletten
+ 1 more products
Pazopanib Viatris 400 mg Filmtabletten
2026-04-012026-09-15Sonstige
Alternatives: N/A
register ↗
🇪🇸 SpainShortage
PAZOPANIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, 60 comprimidos
+ 1 more products
PAZOPANIB GLENMARK 400 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG, 60 comprimidos
2026-05-202026-09-29Existen otros medicamentos con el mismo principio activo y misma vía.
Alternatives: Existe/n otro/s medicamento/s con el mismo principio activo y para la misma vía de administración.
register ↗
🇮🇹 ItalyShortage
PAZOPANIB ZENTIVA
2026-08-31Problemi produttivi
Alternatives: AIFA: an alternative treatment is available (ask your doctor).
register ↗

New register reports per month

2026-04: 22026-05: 12026-06: 02026-07: 02026-08: 22026-042026-08

Full report history (5 register entries)

Every individual register entry for Pazopanibhydrochlorid in the tracked sources, newest first — including resolved and discontinued reports.

Reg.ProductStatusReportedExpected endStated reason
🇮🇹 ITPAZOPANIB ZENTIVAShortage2026-08-31Problemi produttivi
🇪🇸 ESPAZOPANIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG, Shortage2026-08-23Existen otros medicamentos con el mismo principio activo y m
🇪🇸 ESPAZOPANIB GLENMARK 400 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG, 60Shortage2026-05-202026-09-29Existen otros medicamentos con el mismo principio activo y m
🇩🇪 DEPazopanib Viatris 200 mg FilmtablettenShortage2026-04-012026-09-15Sonstige
🇩🇪 DEPazopanib Viatris 400 mg FilmtablettenShortage2026-04-012026-09-15Sonstige

Frequently asked

Is Pazopanibhydrochlorid currently in shortage in Europe?

Yes. As of 9 September 2026, availability issues are reported in: Germany, Spain, Italy. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Pazopanibhydrochlorid shortage expected to end?

Agency prognoses on file range from 2026-09-15 to 2026-09-29. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Pazopanibhydrochlorid?

5 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Pazopanibhydrochlorid availability data come from?

Directly from the official medicines-agency registers that list Pazopanibhydrochlorid: BfArM (Germany), AEMPS CIMA (Spain), AIFA (Italy). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Pazopanibhydrochlorid — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/pazopanibhydrochlorid/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Pazopanibhydrochlorid availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/pazopanibhydrochlorid/">Pazopanibhydrochlorid shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>
Cite: “Pazopanibhydrochlorid: availability status across 3 European registers — European Medicine Shortage Tracker (MobiDoctor), 9 September 2026.” Link this page and the agency record. Statuses come from the linked official registers and can change daily.